CME Group Inc. $CME Stock Acquired by BNP Paribas

BNP Paribas boosted its position in CME Group Inc. (NASDAQ:CME – Free Report) by 436.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 77,555 shares of the financial services provider’s stock after acquiring an additional 63,095 shares during the period. BNP Paribas’ holdings in CME Group were worth $20,342,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CME. First Community Trust NA purchased a new stake in shares of CME Group during the third quarter worth $26,000. North Point Portfolio Managers Corp OH purchased a new position in shares of CME Group during the third quarter valued at approximately $26,000. Mowery & Schoenfeld Wealth Management LLC bought a new position in CME Group in the second quarter worth $28,000. Compass Financial Management LLC raised its position in shares of CME Group by 471.4% in the 3rd quarter. Compass Financial Management LLC now owns 120 shares of the financial services provider’s stock worth $31,000 after purchasing an additional 99 shares during the last quarter. Finally, Atwood & Palmer Inc. boosted its position in shares of CME Group by 285.7% during the third quarter. Atwood & Palmer Inc. now owns 135 shares of the financial services provider’s stock valued at $35,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 87.75% of the company’s stock.

CME Group Stock Up 0.4%

CME Group stock opened at $307.54 on Friday. CME Group Inc. has a 52 week low of $218.31 and a 52 week high of $329.16. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average price is $289.43 and its two-hundred day moving average price is $282.08. The stock has a market cap of $110.08 billion, a price-to-earnings ratio of 25.23, a PEG ratio of 3.75 and a beta of 0.15.

CME Group (NASDAQ:CME – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The financial services provider reported $3.02 EPS for the quarter, beating the consensus estimate of $2.99 by $0.03. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.71 billion. CME Group had a net margin of 63.33% and a return on equity of 16.23%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.68 EPS. On average, analysts expect that CME Group Inc. will post 12.36 EPS for the current fiscal year.

CME Group Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Friday, December 11th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, December 11th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 1.7%. CME Group’s dividend payout ratio is currently 42.66%.

CME Group News Roundup

Investors following CME have been watching these news items:

  • Positive Sentiment: The company announced the first trade in its wind power contracts, extending its product lineup and potentially opening another market for trading and risk management. Article
  • Neutral Sentiment: A report highlights exchange operators’ potential exposure to AI-driven trading, but provides no specific new CME business or financial update. Article
  • Negative Sentiment: CEO Terrence Duffy sold 27,000 shares, reducing his direct holdings by about 43%; General Counsel John Marchese also sold 655 shares. Insider sales can be for personal reasons and do not necessarily signal weaker prospects, but may weigh on sentiment. CEO sale report General counsel sale report

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. CLSA set a $367.00 price target on shares of CME Group in a report on Thursday, October 22nd. UBS Group raised their price objective on CME Group from $270.00 to $310.00 and gave the stock a “neutral” rating in a research report on Thursday, October 22nd. Barclays raised their price objective on shares of CME Group from $281.00 to $321.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 22nd. Piper Sandler restated an “overweight” rating and issued a $330.00 price target (up from $295.00) on shares of CME Group in a research report on Thursday, October 22nd. Finally, TD Cowen lifted their price objective on CME Group from $292.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $314.44.

Check Out Our Latest Analysis on CME Group

Insiders Place Their Bets

In other CME Group news, Director Howard Siegel sold 2,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $303.00, for a total value of $606,000.00. Following the sale, the director owned 19,873 shares of the company’s stock, valued at $6,021,519. The trade was a 9.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Julie Winkler sold 10,079 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $305.15, for a total transaction of $3,075,606.85. Following the sale, the insider directly owned 21,482 shares of the company’s stock, valued at approximately $6,555,232.30. The trade was a 31.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,166 shares of company stock valued at $18,276,512 in the last quarter. 0.30% of the stock is currently owned by insiders.

About CME Group

(Free Report)

CME Group operates a global marketplace for derivatives and other financial products. Through its exchanges—CME, CBOT, NYMEX and COMEX—it offers futures and options contracts tied to interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The company also provides clearing and settlement services, market data and related products. Its electronic trading platform, CME Globex, supports access to its markets by participants around the world, alongside its open-outcry and privately negotiated trading services.

See Also

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.